Safety and Pharmacodynamic Study of a New Formulation, AGI - 101H Vaccine in the Treatment of Advanced Melanoma
Phase 1
Terminated
- Conditions
- Melanoma
- First Posted Date
- 2008-07-16
- Last Posted Date
- 2016-04-22
- Lead Sponsor
- AGIRx Ltd.
- Target Recruit Count
- 5
- Registration Number
- NCT00716495
- Locations
- 🇵🇱
WCO (Great Poland Cancer Centre), Poznan, Poland
© Copyright 2025. All Rights Reserved by MedPath